Physician profile
Kai M Sun
NPI 1023286317
$2,878.92
in general payments reported to CMS, 2019-2025
26 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $296 · 2021: $624 · 2022: $376 · 2023: $264 · 2024: $450 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.52 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $594.51 | 2019-2025 | Wainua, Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $373.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $285.78 | 2021-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $265.03 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $216.37 | 2021-2022 | |
| Penumbra, INC. | $206.87 | 2022-2025 | Indigo System |
| Abbott Laboratories | $159.33 | 2019-2025 | Esprit, Thoratec Heartmate 3 Lvas Implant Kit |
| Heartflow, INC. | $109.01 | 2021 | |
| Amgen INC. | $80.71 | 2019-2023 | Repatha |
| Gilead Sciences, INC. | $65.95 | 2024-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $61.74 | 2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $54.49 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $53.43 | 2024 | Arcalyst |
| Medtronic, INC. | $52.12 | 2021-2025 | Symplicity G3 |
| Medtronic Vascular, INC. | $50.36 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $48.56 | 2025 | |
| Abiomed | $44.59 | 2023 | Impella |
| Vital Connect, INC | $26.18 | 2023 | Vitalpatch Rtm |
| Takeda Pharmaceuticals U.S.A., INC. | $20.04 | 2019 | |
| Philips North America LLC | $17.61 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.24 | 2019 | |
| Amarin Pharma, INC. | $15.79 | 2019 | |
| Cordis US Corp. | $15.70 | 2025 | Mynx Control Venous |
| Actelion Pharmaceuticals US, INC. | $15.20 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.79 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.01 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.